Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443216 in HER2 Expressing Solid Tumors
NCT05013554Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Aug 2021
- Primary completion
- Jan 2024
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of SAR443216 in solid tumor, breast cancer, gastric cancer (GC) and 1 more (5 arms), sponsored by Sanofi. Primary endpoints: Maximum Tolerated Dose / Maximum Administered Dose at Cycle 1, Safety and Tolerability (Adverse Events) up to 7.5 months and 2 more. Started Aug 2021; status: terminated.
02
Drugs
SAR443216
03
Conditions
solid tumorbreast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05013554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013554.